Nephrology Forum

Kidney International (1985) 28, 212–220; doi:10.1038/ki.1985.143

Lead nephropathy

Presentation of the Forum is made possible by grants from CIBA Pharmaceutical Company, Geigy Pharmaceuticals, and Sandoz, Incorporated.

William M Bennett Principle discussant:1

1Oregon Health Sciences University, Portland, Oregon

Correspondence: Dr W Bennett, Head, Division of Nephrology, The Oregon Health Sciences University, 3181 S.W. Sam Jackson Park Road, Portland, Oregon 97201, USA

Top

References

  1. Nriagu JO: Saturnine gout among Roman aristocrats: Did lead poisoning contribute to the fall of the Empire. N Engl J Med 308:660–663, 1983
  2. Emmerson BT: Chronic lead nephropathy. Kidney Int 4:1–5, 1973
  3. Wedeen RP: Poison in the Pot: The Legacy of Lead. Carbondale, Illinois, Southern Illinois University Press, 1984
  4. Wedeen RP: Occupational renal disease. Am J Kidney Dis 3:241–257, 1984
  5. Brynger H, Brunner FP, Chantler C, Donekerwolcke RA, Jacobs C, Kramer P, Selwood HN, Wing AJ: Combined report on regular dialysis and transplantation in Europe. X. 1979. Proc Eur Dial Transplant Assoc 17:4–86, 1980
  6. Yu T: Lead nephropathy and gout. Am J Kidney Dis 2:555–558, 1982
  7. Vander AJ, Taylor DL, Kalitis K, Mouw DR, Victery W: Renal handling of lead in dogs: clearance studies. Am J Physiol 233:F532–538, 1977
  8. Vander AJ, Mouw DR, Cox JC, Johnson B: Lead transport by renal slices and its inhibition by tin. Am J Physiol 236:F373–378, 1979
  9. Victery W, Vander AJ, Mouw DR: Effect of acid-base status on renal excretion of lead (abstract). Proc Int Soc Nephrol 1978, p R6
  10. Hong CD, Hanenson IB, Lerner S, Hammond PB, Pesce AJ, Pollak VE: Occupational exposure to lead: Effects on renal function. Kidney Int 18:489–494, 1980
  11. Hirsch GH: Effect of chronic lead treatment on renal function. Toxicol Appl Pharmacol 25:84–93, 1973
  12. Fowler BA, Kimmel CA, Woods JS, McConnell EE, Grant LD: Chronic low-level lead toxicity in the rat. III. An integrated assessment of long-term toxicity with special reference to the kidney. Toxicol Appl Pharmacol 56:59–77, 1980
  13. Emmerson BT, Mirosch W, Douglas JB: The relative contributions of tubular reabsorption and secretion to urate excretion in lead nephropathy. Aust NZ J Med 4:353–362, 1971
  14. Gonzalez J, Werk EE, Thrasher K, Behar R, Loadholt CG: Renin-aldosterone system and potassium levels in chronic lead intoxication. South Med J 72:433–436, 1979
  15. McAllister RG, Michelakis AM, Sandstead HH: Plasma renin activity in chronic plumbism. Effect of treatment. Arch Intern Med 127:919–923, 1971
  16. Mouw DW, Vander AJ, Cox J, Fleischer N: Acute effects of lead on renal electrolyte excretion and plasma renin activity. Toxicol Appl Pharmacol 46:435–441, 1978
  17. Fleischer N, Mouw DR, Vander AJ: Chronic effects of lead on renin and renal sodium excretion. J Lab Clin Med 95:159–169, 1980
  18. Vesell ES: The influence of host factors on drug response. IV. Occupation. Ration Drug Ther 14:1–5, 1980
  19. Sandstead HH: Trace element interactions. J Lab Clin Med 98:457–462, 1981
  20. Mahaffey KR, Capar SG, Gladen BC, Fowler BA: Concurrent exposure to lead, cadmium and arsenic: Effects on toxicity and tissue metal concentrations in the rat. J Lab Clin Med 98:463–481, 1981
  21. Victery W, Soifer NE, Weiss JS, Vander AJ: Acute effects of lead on the renal handling of zinc in dogs. Toxicol Appl Pharmacol 61:358–367, 1981
  22. Van Esch GJ, Kroes R: The induction of renal tumors by feeding basic lead acetate to mice and hamsters. Br J Cancer 23:765–771, 1969
  23. Neilan BA, Taddeini L, McJilton CE, Handwerger BS: Decreased T cell function in mice exposed to chronic low levels of lead. Clin Exp Immunol 39:746–749, 1980
  24. Cullen MR, Robins JM, Eskenazi B: Adult inorganic lead intoxication: Presentation of 31 new cases and a review of recent advances in the literature. Medicine 62:221–247, 1983
  25. Batumen V, Landy E, Maesaka JK, Wedeen RP: Contribution of lead to hypertension with renal impairment. N Engl J Med 309:17–21, 1983
  26. Emmerson BT, Lecky DS: The lead content of bone in subjects without recognized past lead exposure and in patients with renal disease. Aust Ann Med 12:139–142, 1963
  27. Craswell P, Boyle P, Heazlewood V, Price J, Lloyd M, Baddeley H, Thomas BJ, Thomas BM: Improvements in the diagnosis of lead nephropathy (abstract). Asian Pacific Cong Nephrol 1983, p 24
  28. Maugh TH: Hair: A diagnostic tool to complement blood serum and urine. Science 202:1271–1273, 1978 | PubMed |
  29. Emmerson BT: Chronic lead nephropathy: The diagnostic use of calcium EDTA and the association with gout. Aust Ann Med 12:310–324, 1963 | PubMed |
  30. Emmerson BT: The clinical differentiation of lead gout from primary gout. Arth Rheum 11:623–634, 1968
  31. Inglis JA, Henderson DA, Emmerson BT: The pathology and pathogenesis of chronic lead nephropathy occurring in Queensland. J Pathol 124:65–76, 1978 | Article | PubMed | ChemPort |
  32. Cramer K, Dahlberg L: Incidence of hypertension among lead workers. A follow-up study based on regular control over 20 years. Br J Indust Med 23:101–104, 1966
  33. Beevers DG, Erskine E, Robertson M, Beattie AD, Goldberg A, Campbell BC, Moore MR, Hawthorne VM: Blood lead and hypertension. Lancet 2:1–8, 1976 | PubMed |
  34. Wilson VK, Thomson ML, Dent CE: Aminoaciduria in lead poisoning; case in childhood. Lancet 2:66–68, 1953
  35. Chisholm JJ, Harrison HC, Eberlein WR, Harrison HE: Aminociduria, hypophosphatemia and rickets in lead poisoning. Am J Dis Child 89:159–168, 1955
  36. Landing BH, Nakai H: Histochemical properties of renal lead inclusions and their demonstration in urinary sediment. Am J Clin Pathol 31:499–503, 1959
  37. Choie DD, Richter GW: Lead poisoning: Rapid formation of intranuclear inclusions. Science 177:1194–1195, 1972 | PubMed | ChemPort |
  38. Goyer RA, May P, Gates M, Kringman MR: Lead and protein content of isolated inclusion bodies from kidneys of lead poisoned rats. Lab Invest 22:245–251, 1970 | PubMed | ChemPort |
  39. Wedeen RP, Mallik DK, Batumen V: Detection and treatment of occupational lead nephropathy. Arch Intern Med 139:53–57, 1979 | Article | PubMed | ISI | ChemPort |
  40. Meyer BR, Fischbein A, Rosenman K, Lerman Y, Drayer DE, Reidenberg MM: Increased urinary enzyme excretion in workers exposed to nephrotoxic chemicals. Am J Med 76:989–998, 1984
  41. Piomelli S, Corash L, Corash MB, Seaman C, Mushak P, Glover B, Padgett R: Blood lead concentrations in a remote Himalayan population. Science 210:1135–1137, 1980
  42. Landrigan PJ: Occupational and community exposures to toxic metals: Lead, cadmium, mercury and arsenic. West J Med 137:531–539, 1982
  43. National Institute for Occupational Safety and Health: National Occupational Hazard Society (DHEW Publication No. 78–114), 1978
  44. Yankel AJ, Von Lindern IH, Walter SD: The Silver Valley Lead Study: The relationship between childhood blood lead levels and environmental exposure. J Air Pollut Control Assoc 27:763–767, 1977
  45. Landrigan PJ, Gehlbach SH, Rosenblum BF: Epidemic lead absorption near an ore smelter: The role of particulate lead. N Engl J Med 292:123–129, 1975
  46. Mims B: Smokestacks reminder of lead tragedy. The Sunday Oregonian Portland, Oregon, 12 April 1981, p C3
  47. Caprio RJ, Margulies HL, Joselow MM: Lead absorption in children and its relation to urban traffic densities. Arch Environ Health 28:195–197, 1974
  48. Thun M, Stayner L, Brown D, Waxweiler R: Mining and deaths from chronic renal failure. Lancet 2:606, 1982
  49. Cooper WC, Gaffey WR: Mortality of lead workers. J Occup Med 17:100–107, 1975
  50. Henderson DA: Chronic nephritis in Queensland. Aust Ann Med 4:163–177, 1955
  51. Henderson DA: A follow-up of cases of plumbism in children. Aust Ann Med 3:219–224, 1954
  52. Henderson DA, Inglis JA: The lead content of bone in chronic Bright's disease. Aust Ann Med 6:145–154, 1957
  53. Morgan JM, Burch HB: Comparative tests for diagnosis of lead poisoning. Arch Intern Med 130:335–340, 1972
  54. Baker EL, Landrigan PJ, Barbour AG, Cox DH, Folland DS, Ligo RN, Throckmorton J: Occupational lead poisoning in the United States: Clinical and biochemical findings related to blood lead. Br J Indust Med 36:314–322, 1979
  55. Danilovic V: Chronic nephritis due to ingestion of lead contaminated flour. Br Med J 1:27–28, 1958
  56. Lilis R, Gavrilescu N, Nestorescu B, Dumitriu C, Roventa A: Nephropathy in chronic lead poisoning. Br J Indust Med 25:196–202, 1968
  57. Tepper LB: Renal function subsequent to childhood plumbism. Arch Environ Health 7:76–85, 1963
  58. McCarron DA, Morris CD, Henry HJ, Stanton HL: Blood pressure and nutrient intake in the United States. Science 224:1392–1398, 1984 | PubMed | ChemPort |
  59. Garcia-Palmieri MR, Cruz-Vidal M, Sorlie PD, Tillotson J, Havlik RJ: Milk consumption, calcium intake and decreased hypertension in Puerto Rico. Hypertension 6:322–328, 1984
  60. Mahaffey KR: Nutrient-lead interactions, in Lead Toxicity, edited by Singhal RL, Thomas JA, Philadelphia, Urban and Schwarzenberg, 1980, pp 425–460
  61. Six KM, Goyer RA: Experimental enhancement of lead toxicity by low dietary calcium. J Lab Clin Med 76:933–942, 1970
  62. Six KM, Goyer RA: The influence of iron deficiency on tissue content and toxicity of ingested lead in the rat. J Lab Clin Med 79:128–136, 1972
  63. Colle A, Grimaud JA, Boucherat M, Manuel Y: Lead poisoning in monkeys: functional and histopathological alterations of the kidneys. Toxicology 18:145–148, 1980
  64. Batumen V, Maesaka JK, Haddad B, Tepper E, Landy E, Wedeen RP: The role of lead in gout nephropathy. N Engl J Med 304:520–523, 1981
  65. Reynolds PP: Moonshine and lead. Arth Rheum 26:1057–1064, 1983
  66. Yu TF, Berger L, Dorph DJ, Smith H: Renal function in gout. V. Factors influencing renal hemodynamics. Am J Med 67:766–771, 1979 | PubMed |
  67. Goyer RA, Wilson MH: Lead-induced inclusion bodies. Results of ethylene-diaminetetraacetic acid treatment. Lab Invest 32:149–156, 1975
  68. Porter GA, Bennett WM: Toxic nephropathies, in The Kidney, edited by Brenner B, Rector FC Jr, Philadelphia, Saunders, 1981, p 2060
  69. Wedeen RP, Batumen V, Landy E: The safety of the EDTA lead mobilization test. Environ Res 30:58–62, 1983 | Article | PubMed | ChemPort |
  70. Beattie AD, Briggs JD, Canauan JS, Doyle D, Mullin PJ, Watson AA: Acute lead poisoning: five cases resulting from self-injection of lead and opium. Q J Med 44:275–284, 1975
  71. Yuer L, Marechaud R, Picaud D, Touchard G, Talin d'Eyzac A, Matuchansky C, Patte D: Insuffisance rénale alque au cours d'un saturnisme professionnel. Nouv Presse Med 7:1541–1543, 1978
  72. Pederson RS: Lead poisoning treated with hemodialysis. Scand J Urol Nephrol 12:189–190, 1978
  73. Roberts JL, Fennell JS, Joseph B, Hayashi JA: Treatment of lead encephalopathy with combined hemodialysis and peritoneal dialysis (abstract). Proc Natl Kidney Foundation Mtg, 1982 pp. 27
  74. Khan AJ, Patel U, Rafeeq M, Myerson A, Kumar K, Evans HE: Reversible acute renal failure in lead poisoning. J Pediatr 102:147–149, 1983
  75. Markowitz ME, Rosen JF: Assessment of lead stores in children: Validation of an eight-hour CaNa EDTA test. J Pediatr 104:337–341, 1984
  76. Graziano JH, Leong JK, Friedheim E: 2,3-dimercaptosuccinic acid: A new agent for the treatment of lead poisoning. J Pharmacol Exp Ther 206:696–700, 1978
  77. Friedheim E, Graziano JH, Popovac D, Dragovic D, Kaul B: Treatment of lead poisoning by 2,3-dimercaptosuccinic acid. Lancet 2:1234–1235, 1978
  78. Twarog T, Cherian MG: Chelation of lead by dimercaptopropane sulfonate and a possible diagnostic use. Toxicol Appl Pharmacol 72:550–556, 1984
  79. Aposhian HV: DMSA and DMPS-water soluble antidotes for heavy metal poisoning. Annu Rev Pharmacol Toxicol 23:193–215, 1983

Extra navigation

.
ADVERTISEMENT